At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
PRCT PROCEPT BioRobotics
Pre-Mkt 03-05 04:35:45 EST
26.56
+0.30
+1.14%
High27.08Low26.11Vol1.31M
Open26.48D1 Closing26.26Amplitude3.69%
Mkt Cap1.50BTradable Cap1.42BTotal Shares56.39M
T/O34.73MT/O Rate2.44%Tradable Shares53.56M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Levi & Korsinsky Launches Fraud Probe Into Procept BioRobotics
Reuters  ·  03-04 04:45
Levi & Korsinsky Launches Fraud Probe Into Procept BioRobotics
Stock Track | PROCEPT BioRobotics Plunges 9.39% in After-Hours Trading Following Multiple Analyst Price Target Cuts
Stock Track  ·  03-03 06:38
Stock Track | PROCEPT BioRobotics Plunges 9.39% in After-Hours Trading Following Multiple Analyst Price Target Cuts
Procept BioRobotics price target lowered to $30 from $62 at UBS
TIPRANKS  ·  03-02 22:13
Procept BioRobotics price target lowered to $30 from $62 at UBS
PROCEPT BioRobotics Is Maintained at Buy by Truist Securities
Dow Jones  ·  03-02 22:09
PROCEPT BioRobotics Is Maintained at Buy by Truist Securities
Truist Adjusts Price Target on PROCEPT BioRobotics to $30 From $47, Maintains Buy Rating
MT Newswires Live  ·  03-02 21:55
Truist Adjusts Price Target on PROCEPT BioRobotics to $30 From $47, Maintains Buy Rating
PROCEPT BioRobotics (PRCT) Gets a Buy from Truist Financial
TIPRANKS  ·  03-02 20:57
PROCEPT BioRobotics (PRCT) Gets a Buy from Truist Financial
PROCEPT BioRobotics (PRCT) Is Down 16.8% After Cutting 2026 Outlook And Widening Q4 Losses
Simply Wall St.  ·  03-02
PROCEPT BioRobotics (PRCT) Is Down 16.8% After Cutting 2026 Outlook And Widening Q4 Losses
Stock Track | PROCEPT BioRobotics Plunges 6.90% After Q4 Revenue Miss, Broker Downgrades and Fraud Probe
Stock Track  ·  02-27
Stock Track | PROCEPT BioRobotics Plunges 6.90% After Q4 Revenue Miss, Broker Downgrades and Fraud Probe
Ademi LLP Probes Possible Securities Fraud at Procept BioRobotics
Reuters  ·  02-27
Ademi LLP Probes Possible Securities Fraud at Procept BioRobotics
Procept Biorobotics Publishes Investor Day Presentation on Aquablation Growth and Profitability Strategy
Reuters  ·  02-27
Procept Biorobotics Publishes Investor Day Presentation on Aquablation Growth and Profitability Strategy
PROCEPT BioRobotics Is Maintained at Overweight by Piper Sandler
Dow Jones  ·  02-27
PROCEPT BioRobotics Is Maintained at Overweight by Piper Sandler
PROCEPT BioRobotics Down Over 22%, on Track for Lowest Close Since February 2022 -- Data Talk
Dow Jones  ·  02-27
PROCEPT BioRobotics Down Over 22%, on Track for Lowest Close Since February 2022 -- Data Talk
Procept Biorobotics Shares Slump 23.9% After Q4 Revenue Miss, Multiple Brokerages Cut PT
THOMSON REUTERS  ·  02-27
Procept Biorobotics Shares Slump 23.9% After Q4 Revenue Miss, Multiple Brokerages Cut PT
Oppenheimer Downgrades PROCEPT BioRobotics to Perform From Outperform, Removes $60 Price Target
MT Newswires Live  ·  02-26
Oppenheimer Downgrades PROCEPT BioRobotics to Perform From Outperform, Removes $60 Price Target
Procept Biorobotics : Oppenheimer Cuts to Perform From Outperform
THOMSON REUTERS  ·  02-26
Procept Biorobotics : Oppenheimer Cuts to Perform From Outperform
Top Premarket Decliners
MT Newswires Live  ·  02-26
Top Premarket Decliners
PROCEPT BioRobotics Highlights Growth Strategy at Investor Day
TIPRANKS  ·  02-26
PROCEPT BioRobotics Highlights Growth Strategy at Investor Day
BofA Downgrades PROCEPT BioRobotics to Underperform From Neutral, Price Target is $20
MT Newswires Live  ·  02-26
BofA Downgrades PROCEPT BioRobotics to Underperform From Neutral, Price Target is $20
Procept BioRobotics Forecasts 27%-33% Revenue Growth in 2026
Reuters  ·  02-26
Procept BioRobotics Forecasts 27%-33% Revenue Growth in 2026
PROCEPT BioRobotics® Hosts 2026 Investor Day to Detail Multi-year Financial Outlook and Strategic Plan for Long-Term Growth
GlobeNewswire  ·  02-26
PROCEPT BioRobotics® Hosts 2026 Investor Day to Detail Multi-year Financial Outlook and Strategic Plan for Long-Term Growth

Introduction

Company Name.
PROCEPT BioRobotics
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). It also designs Aquablation therapy for males suffering from lower urinary tract symptoms due to BPH. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in San Jose, California.
Issue price:
--